Past Studies
Where applicable, click on a study name for more information.
-
Prevalence of primary aldosteronism in poorly controlled hypertensive subjects with diabetes
Sponsor: Emory Medical Care Foundation / Emory GCRC
Duration: 2004-2005
-
The effect of rosiglitazone treatment on free fatty acids-induced endothelial dysfunction, hypertension, and insulin resistance in obese subjects with type 2 diabetes
Sponsor: GlaxoSmithKline / Emory University GCRC
Duration: 2004-2006
-
Basal Insulin in the Management of Patients with Diabetic Ketoacidosis
Sponsor: Sanofi-Aventis
Duration: 2005-2007
-
Bilingual Diabetes Education Program for Latinos in Georgia
In partnership with the American Diabetes Association of Georgia.
Sponsor: Georgia Latino Education Program / Healthcare of Georgia Foundation
Duration: 2005-2007
-
Comparative Trial Between Computer-Guided Intravenous Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU
Sponsor: Sanofi-Aventis
Duration: 2005-2007
-
Comparative Trial Between Insulin Glargine Once Daily Versus Sliding Scale Regular Insulin In Hospitalized Patients With Type 2 Diabetes
Sponsor: Sanofi-Aventis
Duration: 2005-2006
-
Efficacy of MK-0431 Monotherapy in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy
Sponsor: Pfizer Pharmaceuticals
Duration: 2005-2006
-
Free Fatty Acid-Induced Hypertension in Obese Subjects
This study aims to determine the mechanisms for FFA-induced hypertension, endothelial dysfunction and insulin resistance in obese patients with and without diabetes.
Sponsor: American Heart Association
Duration: 2005-2007
-
Markers of normoglycemic remission in obese diabetics
This study aims to find a correlation between measures of beta-cell function, muscle insulin-stimulated signal transduction, and muscle signal transduction protein expression in African Americans with Atypical diabetes.
Sponsor: National Institutes of Health
Duration: 2005-2007
-
Molecular mechanism underlying hyperglycemia-induced insulin resistance in skeletal muscle in obese African Americans with hyperglycemic crises
Sponsor: Diabetes Trust Foundation
Duration: 2005-2006
-
Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with Vildagliptin 50 mg bid to Pioglitazone 30 mg Daily as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy
Sponsor: Novartis Pharmaceuticals
Duration: 2005-2006
-
Nutrition and Lifestyle Change Intervention to assess the impact of a nutritional support program in obese elderly African Americans with diabetes.
Sponsor: Project Open Hand
Duration: 2005-2006
-
Pharmaceutical Trial
A Randomized, Open-Label, Multicenter Study Assessing The Effects Of Forced Exubera® Dose Titration On Glycemic Control In Patients With Suboptimally Controlled Type 2 Diabetes On Two Or More Oral Antidiabetic Agents
Sponsor: Pfizer Pharmaceuticals
Duration: 2005-2006
-
Pharmaceutical Trial
NovoLog® Mix 70/30 (biphasic insulin aspart 70/30) bid vs. Once Daily Lantus (insulin glargine) in Subjects with Type 2 Diabetes and Inadequate Glycemic Control on Basal Insulin Plus Oral Antidiabetic Therapy: A Multicenter, Randomized, Open-Label, Parallel Group Study
Sponsor: Novo Nordisk Pharmaceuticals
Duration: 2005-2006
-
Pharmaceutical Trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo In The Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Sponsor: Pfizer Pharmaceuticals
Duration: 2005-2006
-
Comparative Trial Between Insulin Detemir versus NPH Insulin In Hospitalized Patients With Type 2 Diabetes
Sponsor: Novo Nordisk
Duration: 2006-2007
-
Mechanisms Underlying b-cell failure In Obese African-Americans With History Of Hyperglycemic Crises
Studies on the role of glucotoxicity and lipotoxicity in obese African Americans Atypical or Ketosis Prone Diabetes.
Sponsor: American Diabetes Association
Duration: 2003-2006
